Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

PML/RARa Interferes with NRF2 Transcriptional Activity Increasing the Sensitivity to Ascorbate of Acute Promyelocytic Leukemia Cells.

Banella C, Catalano G, Travaglini S, Divona M, Masciarelli S, Guerrera G, Fazi F, Lo Coco F, Voso MT, Noguera N.

Cancers (Basel). 2019 Dec 30;12(1). pii: E95. doi: 10.3390/cancers12010095.

2.

Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.

Niscola P, Noguera NI, Catalano G, Cupelli L, Fratoni S, Giovannini M, Mazzone C, Neri B, Scaramucci L, Trawinska MM, de Fabritiis P, Abruzzese E.

Acta Oncol. 2019 Jun;58(6):888-890. doi: 10.1080/0284186X.2019.1585943. Epub 2019 Mar 8. No abstract available.

PMID:
30848978
3.

PML/RARA inhibits expression of HSP90 and its target AKT.

Piredda ML, Gaur G, Catalano G, Divona M, Banella C, Travaglini S, Puzzangara MC, Voso MT, Lo-Coco F, Noguera NI.

Br J Haematol. 2019 Mar;184(6):937-948. doi: 10.1111/bjh.15715. Epub 2018 Dec 9.

PMID:
30536958
4.

Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation.

Niscola P, Abruzzese E, Trawinska MM, Palombi M, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Fratoni S, Noguera NI, Catalano G, de Fabritiis P.

Acta Oncol. 2017 Oct;56(10):1331-1333. doi: 10.1080/0284186X.2017.1324215. Epub 2017 May 10. No abstract available.

PMID:
28488914
5.

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.

Noguera NI, Pelosi E, Angelini DF, Piredda ML, Guerrera G, Piras E, Battistini L, Massai L, Berardi A, Catalano G, Cicconi L, Castelli G, D'Angiò A, Pasquini L, Graziani G, Fioritoni G, Voso MT, Mastrangelo D, Testa U, Lo-Coco F.

Oncotarget. 2017 May 16;8(20):32550-32565. doi: 10.18632/oncotarget.15925.

6.

Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia.

Niscola P, Neri B, Catalano G, Morino L, Giovannini M, Scaramucci L, Fratoni S, Noguera NI, Cordone I, de Fabritiis P.

Acta Oncol. 2017 Aug;56(8):1120-1121. doi: 10.1080/0284186X.2017.1287947. Epub 2017 Feb 17. No abstract available.

PMID:
28406054
7.

Identification of a potential topoisomerase II "hotspot" DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms.

Piredda ML, Catalano G, Ciardi C, Divona M, Cicconi L, Panetta P, Curzi P, Garza E, Martínez-Losada C, Postorino M, Lo-Coco F, Noguera NI.

Ann Hematol. 2017 Jan;96(1):155-157. doi: 10.1007/s00277-016-2843-3. Epub 2016 Oct 13. No abstract available.

PMID:
27734129
8.

PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Noguera NI, Piredda ML, Taulli R, Catalano G, Angelini G, Gaur G, Nervi C, Voso MT, Lunardi A, Pandolfi PP, Lo-Coco F.

Oncotarget. 2016 Oct 11;7(41):66386-66397. doi: 10.18632/oncotarget.11964.

9.

A case of SRSF2 mutation in chronic lymphocytic leukemia.

Garza E, Del Poeta G, Martínez-Losada C, Catalano G, Borgia L, Piredda ML, Fabiani E, Gattei V, Lo-Coco F, Noguera NI.

Leuk Res Rep. 2016 Jun 23;6:11-4. doi: 10.1016/j.lrr.2016.03.001. eCollection 2016.

10.

Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes.

Garza E, Fabiani E, Noguera N, Panetta P, Piredda ML, Borgia L, Maurillo L, Catalano G, Voso MT, Lo-Coco F.

J Mol Diagn. 2015 Jan;17(1):85-9. doi: 10.1016/j.jmoldx.2014.08.002. Epub 2014 Oct 24.

11.

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.

Niscola P, Tendas A, Scaramucci L, Merola R, Catalano G, de Fabritiis P.

Blood Res. 2014 Jun;49(2):130-7. doi: 10.5045/br.2014.49.2.130. Epub 2014 Jun 25. No abstract available.

12.

Concomitant transformation of monoclonal gammopathy of undetermined significance to multiple myeloma and of essential thrombocythemia to acute biphenotypic leukemia 37 years after initial diagnosis.

Niscola P, Catalano G, Fratoni S, Scaramucci L, de Fabritiis P, Caravita T.

Blood Res. 2013 Sep;48(3):228-30. doi: 10.5045/br.2013.48.3.228. Epub 2013 Sep 25. No abstract available.

13.

Complex and multifaceted therapy-related myeloid neoplasm following laryngeal cancer treated with Cisplatin and radiotherapy.

Niscola P, Catalano G, Tendas A, Giovannini M, Scaramucci L, Neri B, Morino L, Piccioni D, Fratoni S, Perrotti A, de Fabritiis P.

Mediterr J Hematol Infect Dis. 2013 Apr 15;5(1):e2013030. doi: 10.4084/MJHID.2013.030. Print 2013. No abstract available.

14.

Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes.

Niscola P, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Catalano G, Perrotti A, de Fabritiis P.

Support Care Cancer. 2013 Jul;21(7):1803-5. doi: 10.1007/s00520-013-1818-3. Epub 2013 Apr 21. No abstract available.

PMID:
23604522
15.

The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature

Niscola P, Tendas A, Luo XD, Catalano G, Scaramucci L, Cupelli L, Giovannini M, Ferrannini M, Bondanini F, Piccioni D, Dentamaro T, Palumbo R, Perrotti AP, Liu QF, de Fabritiis P.

Cardiovasc Hematol Agents Med Chem. 2013 Mar;11(1):67-76. Review.

PMID:
23016546
16.

The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes.

Niscola P, Tendas A, Cupelli L, Catalano G, Scaramucci L, Giovannini M, Trinchieri V, Sharma A, Efficace F, Cartoni C, Piccioni D, Perrotti A, Dentamaro T, de Fabritiis P, Keefe DM.

Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):362-75. Review.

PMID:
22721442
17.

Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.

Del Poeta G, Del Principe MI, Maurillo L, Rossi FM, Buccisano F, Ammatuna E, Simotti C, Zucchetto A, Catalano G, Bulian P, Bruno A, Venditti A, De Fabritiis P, Gattei V, Amadori S.

Leuk Lymphoma. 2010 Jan;51(1):95-106. doi: 10.3109/10428190903350421.

PMID:
20001236
18.

PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells.

Marfe G, Di Stefano C, Silvestri R, Abruzzese E, Catalano G, Di Renzo L, Filomeni G, Giorda E, La Regina G, Morgante E, Ciriolo MR, Russo MA, Amadori S, Sinibaldi-Salimei P.

BMC Cancer. 2007 Nov 9;7:207.

19.

Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.

Silvestri R, Marfè G, Artico M, La Regina G, Lavecchia A, Novellino E, Morgante E, Di Stefano C, Catalano G, Filomeni G, Abruzzese E, Ciriolo MR, Russo MA, Amadori S, Cirilli R, La Torre F, Sinibaldi Salimei P.

J Med Chem. 2006 Sep 21;49(19):5840-4. Erratum in: J Med Chem. 2006 Nov 30;49(24):7252. Morgante, Manuela [corrected to Morgante, Emanuela].

PMID:
16970408
20.

Imatinib-mesylate for all patients with hypereosinophilic syndrome?

Musto P, Perla G, Minervini MM, Carella AM, Coco FL, Catalano G.

Leuk Res. 2004 Jul;28(7):773-4. No abstract available.

PMID:
15158099

Supplemental Content

Loading ...
Support Center